Review article: vascular effects of PPARs in the context of NASH.

"Declaration of personal interests: G.S. is a scientific consultant for Durect Co, Evive Bio, Glympse, Novartis, Pandion, Surrozen, Terra Firma, Pfizer, Merk, Satellie bio, Zomagen, Cyta Therapeutics, and Pandion. She received royalty from Springer and UpToDate. Dr. Szabo has equity holding in Glympse bio and Ventyx. She is the Editor of Hepatology Communications. J.‐F.D. Advisory committees: Alentis, Astra‐Zeneca, Bayer, Bristol‐Myers Squibb, Enyo, Esai, Falk, Genfit, Gilead Sciences, Intercept, Inventiva, Ipsen, Lilly, Madrigal, Merck, Novartis, Novo‐Nordisk, Roche. Speaking and teaching: Bayer, Bristol‐Myers Squibb, Intercept, Gilead Sciences, Novartis, Roche. F.T. has received research funding from Gilead, Inventiva, BMS and Allergan. S.F. has acted as advisor and/or lecturer for Astra‐Zeneca, Roche, Gilead, Abbvie, Bayer, BMS, MSD, Janssen, Actelion, Astellas, Genfit, Inventiva, Intercept, Genentech, Galmed, Promethera, Coherus, Julius Clinical, CLS Behring, Galapagos, Madrigal and NGM Bio. P.E.R. has received research funding from Terrafirma and acted as a consultant for Mursla and Abbelight, provided training sessions for Cook and received speaker fees from Tillots pharma. J.G.‐S. has received research funding from Gilead, Inventiva, Conatus, Surrozen, GAT Tx and BrudyLab, and acted as a consultant for Ambys, Novo Seeds, Kintsugi Tx, BrudyLab and Terrafirma. Open access funding provided by Inselspital Universitatsspital Bern."

"FUNDING INFORMATION G.S. is supported by NIH grants R01AA015576, R01AA017729 and R01AA0207440. S.F. holds a senior clinical research fellowship from the Research Foundation Flanders (1802154 N). P.E.R. is supported by the Institut National de la Santé et de la Recherche Médicale (ATIP AVENIR), the Agence Nationale pour la Recherche (ANR‐18‐CE14‐0006‐01, RHU QUID‐NASH, ANR‐18‐IDEX‐0001) and Émergence, Ville de Paris, and Fondation ARC. J.G.‐S. is supported by the Instituto de Salud Carlos III (FIS PI20/00220), the CIBEREHD, the Swiss National Science Funds (320030_189252), the Novartis Foundation for Medical‐Biological Research and the Foundation Suisse Contre le Cancer du Foie."